Russia’s Sputnik V vaccine is 91.6 percent effective against symptomatic COVID-19, according to an analysis published in The Lancet on Tuesday that independent experts said allayed transparency concerns over the jab, which Moscow is already rolling out.
NEW—Interim analysis of Russian #COVID19 #vaccine phase 3 trial involving nearly 20,000 participants suggests a two-dose regimen has an efficacy of 91.6% against symptomatic #COVID19. No serious adverse events were deemed to be associated with vaccination. https://t.co/40sM7f2nbS pic.twitter.com/Hzrs34uCWr— The Lancet (@TheLancet) February 2, 2021
The preliminary findings show that the two-dose Sputnik V “has shown high efficacy” and was well tolerated for participants over 18 in final-stage clinical trials, said co-lead author Inna Dolzhikova of Russia’s Gamaleya National Research center for Epidemiology and Microbiology.
Kazakhstan began its vaccination campaign using Russia’s Sputnik VKazakhstan began its coronavirus vaccination campaign Monday with top health officials receiving Russia’s Sputnik V vaccine.The ministry said that the ... Coronavirus
Coronavirus: Algeria says it has discussed with Russia producing Sputnik V vaccineAlgeria said on Sunday it had discussed with Russia the possibility of producing Moscow’s Sputnik V COVID-19 vaccine.Talks to manufacture the vaccine ... Coronavirus
Coronavirus: Hungary grants initial approval for AstraZeneca, Sputnik V vaccinesHungary’s drug regulator has given initial approval for use of Britain’s AstraZeneca and Russia’s Sputnik V vaccines against the coronavirus, Prime ... Coronavirus